Physician profile
Joseph A Gall
NPI 1508938192
$6,487.22
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,074 · 2020: $1,465 · 2021: $1,729 · 2022: $875 · 2023: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $781.83 | 2019-2023 | |
| Pfizer INC. | $635.53 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $632.98 | 2019-2022 | |
| Amgen INC. | $581.27 | 2019-2023 | Prolia, Evenity |
| Astellas Pharma US INC | $546.79 | 2019-2023 | Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $449.57 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $360.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $334.42 | 2019-2023 | |
| Kite Pharma, INC. | $278.90 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $271.70 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $239.98 | 2019-2023 | Provenge |
| Incyte Corporation | $197.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $150.01 | 2019-2023 | Eliquis |
| Gilead Sciences, INC. | $147.28 | 2019 | |
| Janssen Biotech, INC. | $110.26 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asd Specialty Healthcare, LLC | $105.50 | 2019 | |
| Genentech USA, INC. | $98.73 | 2019-2021 | |
| Array Biopharma INC | $94.62 | 2020-2021 | |
| Heron Therapeutics, INC. | $72.23 | 2019 | |
| Glaxosmithkline, LLC. | $69.15 | 2021-2022 | |
| Tesaro, INC. | $68.91 | 2019 | |
| Mylan Institutional INC. | $45.71 | 2019-2020 | |
| Lilly USA, LLC | $38.94 | 2020-2021 | |
| Dova Pharmaceuticals | $35.35 | 2019-2021 | |
| Genzyme Corporation | $34.89 | 2019-2021 | |
| Secura Bio, INC. | $22.94 | 2020 | |
| Amneal Pharmaceuticals LLC | $21.49 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $21.31 | 2019 | |
| Seqirus USA INC | $13.69 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.12 | 2020 | |
| Circassia INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.